Estudos de relação estrutura atividade e docking - UFRJ

90HEDSTROM, L. Serine protease mechanism and specificity. Chem Rev, v. 102, 12, p. 4501-24, 2002.HEDSTROM, L.; MOORMAN, A. R.; DOBBS, J.; ABELES, R. H. Suicide inactivation of chymotrypsin bybenzoxazinones. Biochemistry, v. 23, 8, p. 1753-9, 1984.HEHRE, W. J. A Guide to Molecular Mechanisms and Quantum Chemical Calculations. . INC, W. 2003.HEMMATEENEJAD, B.; ELYASI, M. A segmented principal component analysis-regression approach toquantitative structure-activity relationship modeling. Anal Chim Acta, v. 646, 1-2, p. 30-8, 2009.HEWLETT, G.; HALLENBERGER, S.; RUBSAMEN-WAIGMANN, H. Antivirals against DNA viruses(hepatitis B and the herpes viruses). Curr Opin Pharmacol, v. 4, 5, p. 453-64, 2004.HONJO, K.; VAN REEKUM, R.; VERHOEFF, N. P. Alzheimer's disease and infection: do infectious agentscontribute to progression of Alzheimer's disease? Alzheimers Dement, v. 5, 4, p. 348-60, 2009.HOOG, S. S.; SMITH, W. W.; QIU, X.; JANSON, C. A.; HELLMIG, B.; MCQUENEY, M. S.; O'DONNELL,K.; O'SHANNESSY, D.; DILELLA, A. G.; DEBOUCK, C.; ABDEL-MEGUID, S. S. Active site cavity ofherpesvirus proteases revealed by the crystal structure of herpes simplex virus protease/inhibitor complex.Biochemistry, v. 36, 46, p. 14023-9, 1997.HSIEH, P. W.; HWANG, T. L.; WU, C. C.; CHANG, F. R.; WANG, T. W.; WU, Y. C. The evaluation of 2,8-disubstituted benzoxazinone derivatives as anti-inflammatory and anti-platelet aggregation agents. Bioorg MedChem Lett, v. 15, 11, p. 2786-9, 2005.HUEY, R.; MORRIS, G. M.; OLSON, A. J.; GOODSELL, D. S. A semiempirical free energy force field withcharge-based desolvation. J Comput Chem, v. 28, 6, p. 1145-52, 2007.JAKOBSEN, P.; PEDERSEN, B. R.; PERSSON, E. Inhibitors of the tissue factor/factor VIIa-inducedcoagulation: synthesis and in vitro evaluation of novel specific 2-aryl substituted 4H-3,1-benzoxazin-4-ones.Bioorg Med Chem, v. 8, 8, p. 2095-103, 2000.JARVEST, R. L.; PARRATT, M. J.; DEBOUCK, C. M.; GORNIAK, J. G.; JENNINGS, L. J.;SERAFINOWSKA, H. T.; STRICKLER, J. E. Inhibition of HSV-1 protease by benzoxazinones. Bioorganicand Medicinal Chemistry Letters, v. 6, 20, p. 2463-2466, 1996.KHAYAT, R.; BATRA, R.; QIAN, C.; HALMOS, T.; BAILEY, M.; TONG, L. Structural and biochemicalstudies of inhibitor binding to human cytomegalovirus protease. Biochemistry, v. 42, 4, p. 885-91, 2003.KIEFER, F.; ARNOLD, K.; KUNZLI, M.; BORDOLI, L.; SCHWEDE, T. The SWISS-MODEL Repository andassociated resources. Nucleic Acids Res, v. 37, Database issue, p. D387-92, 2009.KITCHEN, D. B.; DECORNEZ, H.; FURR, J. R.; BAJORATH, J. Docking and scoring in virtual screening fordrug discovery: methods and applications. Nat Rev Drug Discov, v. 3, 11, p. 935-49, 2004.KOSHLAND, D. E. The Role of Flexibility in Enzyme Action. Cold Spring Harb Symp Quant Biol, v. 28, p.473-482, 1963.KRAUSSLICH, H. G.; WIMMER, E. Viral proteinases. Annu Rev Biochem, v. 57, p. 701-54, 1988.KUHLMANN, I.; MINIHANE, A. M.; HUEBBE, P.; NEBEL, A.; RIMBACH, G. Apolipoprotein E genotypeand hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis, v. 9, p. 8, 2010.LAL, R.; ARNSDORF, M. F. Multidimensional atomic force microscopy for drug discovery: a versatile tool fordefining targets, designing therapeutics and monitoring their efficacy. Life Sci, v. 86, 15-16, p. 545-62, 2010.LASKOWSKI, R. A. PDBsum: summaries and analyses of PDB structures. Nucleic Acids Res, v. 29, 1, p.221-222, 2001.